Lin Wu

17.8k citations

238 papers · 5.2k · 3 hit papers · h-index 34

Impact in

Oncology top 1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Oncology 137
- Lung Cancer Research Studies 60
- Cancer Immunotherapy and Biomarkers 37
- Colorectal Cancer Treatments and Studies 21
- Peptidase Inhibition and Analysis 16
Pulmonary and Respiratory Medicine 116
- Lung Cancer Treatments and Mutations 100
- Lung Cancer Diagnosis and Treatment 32
- Gastric Cancer Management and Outcomes 11

Co-authors: Masaaki Moriya (3 shared papers)Arthur P. Grollman (4 shared papers)Julie Tsai (5 shared papers)Robert J. Turesky (2 shared papers)Ying Cheng (47 shared papers)Yi‐Long Wu (24 shared papers)Tony Mok (10 shared papers)Peter Meldgaard (3 shared papers)
Journals: Journal of Clinical Oncology (47 papers)Annals of Oncology (28 papers)Journal of Thoracic Oncology (18 papers)Cancer Research (7 papers)ESMO Open (5 papers)
Partner nations: China United States Switzerland

In The Last Decade

Lin Wu

213 papers receiving 5.1k citations

Lin Wu's Hit Papers

align trajectories log scale

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy 2015 · 368 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Clinical Cancer Research
2012 Proceedings of the National Academy of Sciences
2007 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Lin Wu

Since Specialization

Citations

This map shows the geographic impact of Lin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Wu more than expected).

Fields of papers citing papers by Lin Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Wu. The network helps show where Lin Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Lin Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lin Wu Line = papers co-authored together Lin Wu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 238 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Aristolochic acid and the etiology of endemic (Balkan) nephropathy Proceedings of the National Academy of Sciences ·Arthur P. Grollman, Shinya Shibutani, Masaaki Moriya, Frederick W. Miller, Lin Wu, Ute M. Moll, Naomi Suzuki, Andrea Fernandes, Thomas A. Rosenquist, Zvonimir Medverec, Krunoslav Jakovina, Branko Brdar, Neda Slade, Robert J. Turesky, Angela K. Goodenough, Robert Rieger, Mato Vukelić, Bojan Jelaković Hit paper breakdown →	2007	453
2	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Clinical Cancer Research ·Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, (unknown), Barbara Klughammer, David S. Shames, Lin Wu Hit paper breakdown →	2015	368
3	Aristolochic acid-associated urothelial cancer in Taiwan Proceedings of the National Academy of Sciences ·Chung‐Hsin Chen, Kathleen G. Dickman, Masaaki Moriya, Jiří Zavadil, Viktoriya S. Sidorenko, Karen L. Edwards, Dmitri V. Gnatenko, Lin Wu, Robert J. Turesky, Xue‐Ru Wu, Yeong‐Shiau Pu, Arthur P. Grollman Hit paper breakdown →	2012	315
4	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial Journal of Thoracic Oncology ·Yi‐Long Wu, Shun Lü, Ying Cheng, Caicun Zhou, Jie Wang, Tony Mok, Li Zhang, Hai-Yan Tu, Lin Wu, Jifeng Feng, Yiping Zhang, Alexander Luft, Jianying Zhou, Zhiyong Ma, You Lü, Chengping Hu, Yuankai Shi, Christine Baudelet, Junliang Cai, Jianhua Chang	2019	267
5	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab Breast Cancer Research and Treatment ·Stefan Glück, Jeffrey S. Ross, Melanie Royce, Edward McKenna, Charles M. Perou, Eli Avisar, Lin Wu	2011	185
6	p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study JNCI Journal of the National Cancer Institute ·Steven A. Ahrendt, Ying Hu, Marko Buta, Michael McDermott, Nicole Benoit, Stephen C. Yang, Lin Wu, David Sidransky	2003	170
7	The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype Leukemia ·Frank Dicker, Hannes Herholz, Susanne Schnittger, Aki Nakao, Nancy Patten, Lin Wu, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach	2008	159
8	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib Cancer ·Boe Sandahl Sørensen, Lin Wu, Wen Wei, Julie Tsai, Britta Weber, Ebba Nexø, Peter Meldgaard	2014	157
9	Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene Molecular Medicine ·Lin Wu, Arnold J. Levine	1997	148
10	The Impact of Pharmacogenomics on Postoperative Nausea and Vomiting Anesthesiology ·Keith Candiotti, David J. Birnbach, David A. Lubarsky, Fani Nhuch, Aimee Kamat, Walter Koch, Michele Nikoloff, Lin Wu, David Andrews	2005	129
11	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays BMC Cancer ·Britta Weber, Peter Meldgaard, Henrik Hager, Lin Wu, Wen Wei, Julie Tsai, Azza A. Khalil, Ebba Nexø, Boe Sandahl Sørensen	2014	127
12	Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma Diagnostic Molecular Pathology ·Harkanwal Halait, Kelli DeMartin, Sweta Shah, Stephen Soviero, Rachel Langland, Suzanne Cheng, Grantland Hillman, Lin Wu, H. Jeffrey Lawrence	2012	117
13	Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study British Journal of Cancer ·Ying Cheng, Qiming Wang, Kai Li, Jianhua Shi, Ying Liu, Lin Wu, Baohui Han, Gongyan Chen, Jianxing He, Jie Wang, Donghua Lou, Hao Yu, Shan-chun Wang, Haifeng Qin, Xiaoling Li	2021	107
14	p53 Gene and Protein Status: The Role of p53 Alterations in Predicting Outcome in Patients With Bladder Cancer Journal of Clinical Oncology ·Ben George, Ram H. Datar, Lin Wu, Jie Cai, Nancy Patten, Stephen Beil, Susan Groshen, John P. Stein, Donald G. Skinner, Peter A. Jones, Richard J. Côté	2007	101
15	Alternatively Spliced Forms in the Carboxy-Terminal Domain of the p53 Protein Regulate Its Ability to Promote Annealing of Complementary Single Strands of Nucleic Acids Molecular and Cellular Biology ·Lin Wu, J. Henri Bayle, Brian Elenbaas, Nikola P. Pavletich, Arnold J. Levine	1995	99
16	TP53 Mutational signature for aristolochic acid: an environmental carcinogen International Journal of Cancer ·Masaaki Moriya, Neda Slade, Branko Brdar, Zvonimir Medverec, Karla Tomić, Bojan Jelaković, Lin Wu, Sim Truong, Andrea Fernandes, Arthur P. Grollman	2011	84
17	Teledentistry: a systematic review of clinical outcomes, utilization and costs. PubMed ·Susan J. Daniel, Lin Wu, Sajeesh Kumar	2013	78
18	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations Journal of Thoracic Oncology ·Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, Tudor–Eliade Ciuleanu, Tony Mok, Martin Reck, Eng Huat Tan, Paul Delmar, Gaëlle Klingelschmitt, Anny-Yue Yin, Olivia Spleiss, Lin Wu, David S. Shames	2016	78
19	Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway Frontiers in Oncology ·Masha Huang, Junyan Liu, Xiaobo Xia, Yingzi Liu, Xi Li, Ji‐Ye Yin, Jingbo Peng, Lin Wu, Wei Zhang, Hong‐Hao Zhou, Zhaoqian Liu	2019	78
20	LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC Annals of Oncology ·Tina Cascone, Mark M. Awad, J.D. Spicer, Jie He, Shun Lü, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, (unknown), Luboš Petruželka, Lin Wu, J-L. Pujol, Hiroyuki Ito, C. Coronado Erdmann, Padma Sathyanarayana, S. Meadows–Shropshire, M. Provencio Pulla	2023	69

About Lin Wu

Lin Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 238 papers that have together received 5.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (100 papers), Lung Cancer Research Studies (60 papers), Cancer Immunotherapy and Biomarkers (37 papers), Lung Cancer Diagnosis and Treatment (32 papers), Colorectal Cancer Treatments and Studies (21 papers), Cancer Genomics and Diagnostics (18 papers), Peptidase Inhibition and Analysis (16 papers) and Gastric Cancer Management and Outcomes (11 papers). The work is most often cited by research in Oncology (2.1k citations), Cancer Research (1.1k citations), Pulmonary and Respiratory Medicine (1.6k citations), Pharmacology (366 citations) and General Dentistry (57 citations). Lin Wu has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Masaaki Moriya, Arthur P. Grollman, Julie Tsai, Robert J. Turesky, Ying Cheng, Yi‐Long Wu, Tony Mok, Peter Meldgaard, Britta Weber and Boe Sandahl Sørensen. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Cancer Research and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Lin Wu

Impact in

Papers in i

In The Last Decade

Lin Wu

Lin Wu's Hit Papers

Peers

Countries citing papers authored by Lin Wu

Fields of papers citing papers by Lin Wu

All Works

About Lin Wu

Explore authors with similar magnitude of impact

Papers in